Who is sponsoring TERIKIDS?

TERIKIDS is sponsored by Genzyme, a Sanofi Company.

What condition does TERIKIDS study?

TERIKIDS studies Multiple Sclerosis.

What drugs are being tested in TERIKIDS?

Interventions: Teriflunomide, Placebo.

What is the status of TERIKIDS?

TERIKIDS is currently COMPLETED.

Last reviewed 2025-02-06 · How we verify

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (TERIKIDS)

NCT02201108 PHASE3 COMPLETED Results posted

Primary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing forms of multiple sclerosis (MS). Secondary Objective: * To assess the effect of teriflunomide in comparison to placebo on disease activity/progression measured by brain magnetic resonance imaging (MRI) and on cognitive function. * To evaluate the safety and tolerability of teriflunomide in comparison to placebo. * To evaluate the pharmacokinetics (PK) of teriflunomide.

Details

Lead sponsor	Genzyme, a Sanofi Company
Phase	PHASE3
Status	COMPLETED
Enrolment	166
Start date	Wed Jul 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multiple Sclerosis

Interventions

Teriflunomide
Placebo

Countries

Lebanon, Tunisia, Netherlands, Russia, Belgium, Estonia, Lithuania, Bulgaria, Morocco, Portugal, United States, France, Greece, Serbia, Israel, Canada, Spain, Ukraine, United Kingdom, China, North Macedonia, Turkey (Türkiye)